Century Therapeutics, Inc.
IPSCNASDAQHealthcare● Active
$2.12
$-0.01(-0.47%)
Market Cap$183527105
P/E Ratio—
52W High$3.04
52W Low$0.435
Century Therapeutics, Inc. (IPSC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IPSC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.11B | $0.01B | $0.00B | $0.01B | $0.00B |
| Cost of Revenue | $0.01B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.10B | $0.01B | $0.00B | $0.01B | ($0.00B) |
| Gross Margin %(computed) | 88.00% | 100.00% | 100.00% | 100.00% | — |
| Operating Expenses | |||||
| R&D Expenses | $0.10B | $0.11B | $0.09B | $0.10B | $0.08B |
| G&A Expenses | $0.02B | $0.03B | $0.03B | $0.03B | $0.00B |
| Total Operating Expenses | $0.11B | $0.14B | $0.15B | $0.14B | $0.09B |
| Operating Income | ($0.02B) | ($0.14B) | ($0.15B) | ($0.13B) | ($0.09B) |
| Operating Margin %(computed) | -13.78% | — | — | — | — |
| Interest Income | $0.01B | $0.01B | $0.01B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.01B) | ($0.12B) | ($0.13B) | ($0.13B) | ($0.10B) |
| Income Tax Expense | ($0.00B) | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.13B) | ($0.14B) | ($0.13B) | ($0.10B) |
| Net Margin %(computed) | -8.78% | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.11 | $-1.61 | $-2.30 | $-2.27 | $-1.74 |
| Wtd Avg Shares | 0.09B | 0.08B | 0.06B | 0.06B | 0.06B |
| EBITDA | ($0.00B) | ($0.11B) | ($0.12B) | ($0.12B) | ($0.09B) |
| EBITDA Margin %(computed) | -1.78% | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · USD · B
Explore more Century Therapeutics, Inc. data
About Century Therapeutics, Inc. (IPSC) Income Statement
Century Therapeutics, Inc. (IPSC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, IPSC reported revenue of $0.11B, gross profit of $0.10B (gross margin 88.00%), and net income of ($0.01B) — a net profit margin of -8.78%.
Frequently asked questions
IPSC · 4 questionsCentury Therapeutics, Inc. (IPSC) reported revenue of $0.11B for 2025, up 1556.8% year-over-year.
IPSC revenueIPSC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09